Overview of Alerfin

Quick Facts

Property	Description
Active Ingredient	Chlorphenamine Maleate
Pharmacological Class	Antihistamine (First-generation H1 antagonist)
Origin	Synthetic
Common Forms	Oral tablet, Oral solution/syrup
General Purpose	Symptomatic relief of allergic reactions

Defining Alerfin: Composition, Identity, and Positioning

Alerfin is a medicinal product containing the active ingredient Chlorphenamine Maleate, which is classified within the pharmacological class of antihistamines. Specifically, it functions as a first-generation histamine H1 receptor antagonist, meaning it is chemically designed to block the effects of histamine released during the body's allergic response. Chlorphenamine is a synthetic compound, assuring a consistent standard for therapeutic effect in its manufacture. This antagonistic action is clinically recognized for providing effective symptomatic relief from the discomfort caused by various allergic triggers, such as the symptoms associated with seasonal allergic rhinitis.

General Purpose: Function as a Symptomatic Reliever

The general purpose of Alerfin is to offer symptomatic relief by controlling the body’s exaggerated response to allergens, such as those that precipitate the symptoms of common allergies. By binding to the H1 receptors, Chlorphenamine reduces the effects of histamine on nerve endings and capillaries, which are responsible for causing signs like itching, sneezing, and a runny nose. This pharmacological mechanism leads to the suppression of immediate, uncomfortable signs of an allergy, defining its role as a reliever agent for allergic episodes rather than a long-term preventive treatment for the underlying immunological cause.

Regulatory References

What side effects are possible with Alerfin?

Possible Side Effects and Safety Information

Adverse Reaction Scope

The official safety documents classify adverse reactions based on frequency and the body system affected (System-Organ Class or SOC). The most frequently documented effects concern the central nervous system (CNS).

Classification	Examples of Officially Listed Reactions
Very Common (ge 1/10)	Sedation, Somnolence (Drowsiness)
Common (ge 1/100 to < 1/10)	Dizziness, Headache, Dry mouth, Nausea, Fatigue, Blurred Vision, Disturbance in attention

Adverse reactions reported with Unknown Frequency (cannot be estimated from available data) span multiple system-organ classes, including Gastrointestinal disorders (e.g., vomiting, abdominal pain), Skin and subcutaneous disorders (e.g., rash, photosensitivity), Psychiatric disorders (e.g., confusion, irritability), and Renal and urinary disorders (e.g., urinary retention).

Serious Adverse Reactions and Population-Specific Safety Notes

Serious Reactions: Rare but clinically significant reactions documented in regulatory sources include Blood Dyscrasias (such as haemolytic anaemia), Hepatitis (including jaundice), and severe Hypersensitivity/Anaphylactic reactions.

Population-Specific Considerations: The official labeling indicates that children and older adults are more susceptible to neurological anticholinergic effects, which may include paradoxical excitation (restlessness, nervousness). Caution is noted for use during the third trimester of pregnancy due to the potential for reactions in the newborn and the substance may be secreted in breast milk, potentially inhibiting lactation.

Safety-Related Restrictions: The drug's documented anticholinergic properties are associated with effects such as blurred vision and psychomotor impairment. Official documents note that caution is required in individuals with pre-existing conditions sensitive to these effects, such as glaucoma (raised intra-ocular pressure), prostatic hypertrophy, and severe hypertension.

Connection to the Overall Safety Profile

The regulatory safety profile highlights CNS effects, particularly sedation, as the most expected outcome of exposure. The comprehensive listing of adverse reactions across diverse system-organ classes, even those of unknown frequency, establishes the breadth of possible effects reported to regulators. These documented safety boundaries confirm that caution is officially noted when the medicine is used in specific populations and concurrently with other sedating substances.

Overdose and Emergency Response

Overdose Manifestations and Severe Outcomes

An overdose of Alerfin (Chlorphenamine Maleate) is officially documented to primarily affect the central nervous system (CNS). Overexposure may result in a spectrum of CNS manifestations, including profound depression, such as extreme drowsiness, confusion, and disorientation, potentially progressing to coma. Conversely, documented signs of CNS excitement, including agitation, hallucinations, and tremors, may also occur. Overdose carries the risk of life-threatening outcomes, specifically respiratory depression and serious cardiac rhythm disturbances (arrhythmias) accompanied by severe hypotension. The official profile also documents signs of anticholinergic toxicity, such as dilated pupils, dry mouth, and an inability to urinate (urinary retention).

When to Seek Immediate Medical Help

All instances of suspected overdose require that immediate medical attention be sought. Regulatory guidance explicitly mandates contacting emergency services if the person experiences a seizure, has trouble breathing, collapses, or cannot be awakened. Continuous cardiac monitoring and hospital observation are required due to the potential for severe cardiovascular effects. Management focuses on symptomatic and supportive treatment, as official regulatory information indicates that no specific antidote is known. Certain populations, specifically children and the elderly, are documented to be more susceptible to CNS manifestations like heightened excitement during overexposure.

Therapeutic Uses of Alerfin

What Alerfin Treats: Main Uses and Benefits

Alerfin is commonly used to help with symptomatic relief across domains where additional symptomatic support is needed, primarily for conditions involving episodic or fluctuating manifestations associated with acute or episodic changes. Its use includes addressing groups of symptoms that may become intense or disruptive in contexts like seasonal and perennial allergic rhinitis (hay fever).

In the respiratory domain, Alerfin is relevant for easing symptoms related to heightened physiological activity, such as frequent sneezing, runny nose (rhinorrhea), and nasal or throat itchiness. It is also relevant for managing symptoms that interfere with daily comfort, including ocular manifestations and the cutaneous symptoms associated with hives (urticaria) and symptomatic itching (pruritus). Applied in clinical settings that involve acute or disruptive symptom patterns, the medication is often used when symptoms intensify or overlap with those of the common cold. This short-term symptomatic assistance provides support that helps ease the overall symptom burden, contributes to supporting functional comfort, and helps improve day-to-day comfort during symptomatic periods.

Quick Fact: Relief for Symptomatic Episodes

Property	Description
Therapeutic Scope	Supports symptomatic relief across multiple domains
Core Indications	Allergic rhinitis, Hay fever, Urticaria
Symptoms Addressed	Sneezing, Itching, Runny nose, Hives
Typical Context	Episodic symptom escalation

Regulatory References

NIH MedlinePlus overview

Eligibility and Restrictions for Use

Alerfin (Chlorphenamine Maleate) is subject to specific eligibility rules defining who can and cannot use the medicine, as documented in government regulatory labeling.

Absolute Contraindications

Use is prohibited for patients with known hypersensitivity to the active ingredient or who have received a Monoamine Oxidase Inhibitor (MAOI) within the last 14 days. The medicine is also contraindicated for newborn and premature infants, as well as patients with narrow-angle glaucoma or symptomatic conditions leading to urinary retention.

Age-Based Restrictions

The medicine is generally not recommended for children under the age of 6 years for typical over-the-counter use. While established for adults, older adults are advised to use caution, often requiring a lower daily dose due to increased susceptibility to effects like confusion.

Conditional Use and Restrictions

Caution is required for populations with pre-existing conditions, including hepatic (liver) impairment and renal (kidney) impairment. Similarly, patients with severe cardiovascular disease or certain breathing problems (e.g., chronic bronchitis) should use the drug with caution. Use during pregnancy (especially the third trimester) and lactation is generally not recommended unless considered essential by a physician. Official labeling also explicitly warns against using the medicine to make a child sleepy.

What should I know about interactions with other medicines?

️ Interaction Map: Interactions with other medicines and products — official regulatory information for Alerfin

Interaction Scope and Classification

Medicinal product categories with documented interactions include Monoamine Oxidase Inhibitors (MAOIs), Central Nervous System (CNS) Depressants, and Anticholinergic Drugs. MAOIs represent a contraindication, enforced by a 14-day timing rule requiring separation from Alerfin administration. The primary mechanistic basis for the majority of severe interactions is pharmacodynamic, resulting in additive CNS depression (with agents such as Alcohol and hypnotics) and enhanced antimuscarinic action (with agents like Tricyclic Antidepressants). Phenytoin is listed separately due to a specific pharmacokinetic interaction where Alerfin inhibits its metabolism, potentially leading to increased Phenytoin exposure and toxicity. Official labeling further advises against concurrent use with other antihistamine-containing products.

Official Interaction Statements

Co-administration with Monoamine Oxidase Inhibitors (MAOIs) is formally contraindicated due to the intensification of anticholinergic effects.
Alcohol and other CNS depressants may cause an additive CNS depressant effect, enhancing sedation.
Co-administration with Phenytoin may result in the inhibition of its metabolism, increasing systemic exposure and risking toxicity.
Chlorphenamine Maleate is documented as a major substrate of the CYP2D6 hepatic enzyme.

Connection to the overall interaction profile: The regulatory documents primarily define the interaction structure through pharmacodynamic risks of additive CNS effects with various substance classes. This profile establishes an absolute prohibition for co-use with MAOIs, enforced by a time-specific restriction, while also documenting a specific pharmacokinetic interaction with Phenytoin.

Mechanism of Action

Alerfin is a selective inverse agonist of the histamine H1 receptor. This receptor, when activated by endogenous histamine, triggers cellular events associated with inflammation. Alerfin binds to the H1 receptor site with high affinity, stabilizing it in an inactive conformation. This action competitively prevents the binding of endogenous histamine, thereby inhibiting the receptor's downstream signaling pathway.

The blockade of the H1 receptor directly results in a modulation of the cellular mechanisms involved in the inflammatory cascade. Specifically, the inhibition of histamine signaling influences the activity of key intracellular components, including the regulation of the NF-kappa B pathway. This effect influences the release of pro-inflammatory mediators from activated cells.

At the cellular level, the antagonism and subsequent pathway modulation influence the behavior of key immune effector cells. This primarily includes the stabilization of mast cell and basophil membranes, which are responsible for the storage and release of histamine and other potent mediators. By influencing the degranulation process of these cells, Alerfin restricts the initiation and maintenance of the histamine-driven component of the physiological response.

Dosage and Administration Information

Alerfin (Chlorphenamine Maleate) is administered using established regimens. The routes include Oral administration, using tablets or solution/syrup, and Parenteral administration (Intramuscular, Subcutaneous, or Intravenous injection).

Standard Dosing and Frequency

The typical adult single dose for the Oral Immediate-Release form is 4 mg, to be administered every 4 to 6 hours as needed. The total dose must not exceed a maximum of 24 mg in a 24-hour period. Extended-release formulations are administered less frequently, typically every 8 to 12 hours. For acute situations, the injectable form is administered at a dose of 10 mg to 20 mg per use.

Administration Conditions and Constraints

The oral forms may be taken with or without food. When using the liquid solution, it is required to use an accurate milliliter measuring device to ensure the correct dose is administered. For the intravenous route, the injection must be delivered slowly over one minute. Use is generally intended for short-term symptomatic management, and continuous use should not exceed two weeks without clinical consultation.

Population-Specific Use

A lower maximum daily dose may be necessary for older adults (e.g., maximum 12 mg/day). For pediatric patients aged 6 to under 12 years, the immediate-release dose is 2 mg every 4 to 6 hours, with a maximum limit of 12 mg in 24 hours. Patients with hepatic or renal impairment are directed to seek medical advice regarding use and dosing.

Recent Clinical Evidence

Research evidence / Overview of studies for Alerfin (Chlorphenamine Maleate)

This section describes the types of clinical studies that have been conducted for Alerfin, the specific outcomes researchers examined, and areas where more research is still needed, according to official and peer-reviewed sources.

Evidence for Use in Seasonal and Perennial Allergic Rhinitis (Hay Fever)

The foundation of research for Alerfin in this area rests on numerous historical short-term Randomized Controlled Trials (RCTs). These studies were designed to explore how symptoms change over time when compared against a placebo or other active treatments. Researchers monitored outcomes related to physical discomfort, primarily assessing patient-reported experiences through scales that tracked changes in the severity of sneezing, runny nose, and ocular (eye) itching. The research examined conditions characterized by fluctuating or episodic manifestations.

The findings described patterns observed in the studies related to a reported change in these acute symptoms, contributing to the broader evidence landscape for conditions characterized by fluctuating or episodic manifestations. Studies monitored outcomes that led to the compound's classification as a first-generation antihistamine.

Evidence for Use in Acute and Chronic Urticaria (Hives) and Itching

Research exploring Alerfin's observation in hives (urticaria) and symptomatic itching (pruritus) primarily involves older comparative trials and later inclusion in systematic reviews that guide anti-allergic care protocols. Studies explored outcomes related to physical discomfort, such as the change in itching severity and the change in the number and size of the wheals (hives). These outcomes capture phases of heightened symptom activity associated with acute or disruptive episodes.

Studies focusing on episodes where symptoms become more noticeable reported how symptoms evolved in the observed populations, particularly in acute settings. This evidence contributes to the broader evidence landscape regarding episodic symptom management.

What is Still Uncertain About Alerfin's Research Evidence

Several key limitations exist in the current research landscape:

Evidence Quality and Age: Much of the definitive evidence is historical, and a lack of recent, large-scale comparative trials means that comparative evidence is lacking against modern treatments.
Subgroup Findings: Data for certain groups, such as children and older adults, remain insufficient in recent literature, and subgroup findings are uncertain.
Long-Term Effects: There is limited information for long-term outcomes or the consequences of prolonged, continuous use. Evidence highlights what is known about short-term symptom patterns, but certainty remains low for long-term maintenance outcomes.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Alerfin (FAQ)

Q: How quickly can a person expect Alerfin to start working?

Official product information indicates that the effects of the oral medicine typically begin to develop within 30 minutes after taking a dose. The effects observed are intended to help address acute allergic symptoms.

Q: How long does the effect of one dose of Alerfin typically last?

Official product information states that the effects of an oral dose typically last for 4 to 6 hours. This duration reflects the recommended interval for taking the immediate-release formulation.

Q: Is Alerfin available without a prescription?

The active ingredient in Alerfin is widely available in many regions as an Over-the-Counter (OTC) or Pharmacy-only medicine. This legal status means it can be purchased without a prescription.

Q: Is there a generic version of Alerfin available?

Yes, the active ingredient in Alerfin is Chlorphenamine Maleate, which is the generic name for the compound. This generic form is widely available as a generic medication.

Q: Is Alerfin a steroid?

No, Alerfin is not a steroid. The medicine is classified as a first-generation antihistamine, which works by blocking histamine receptors in the body. It belongs to a completely different pharmacological drug class than steroids.

Q: How does Alerfin compare to other common allergy medicines (non-specific comparison)?

Official regulatory documents do not contain specific claims comparing this medicine’s efficacy or safety directly against modern, newer-generation allergy medicines. Much of the definitive research for this compound is historical.

Q: Does the time of day matter when taking Alerfin?

The medicine is associated with a high risk of drowsiness and sedation. For this reason, some specific population guidelines, such as those for older adults or for certain extended-release formulations, suggest that the dose may be taken at bedtime. The time of day can influence the level of alertness required for daily activities.

Q: Is Alerfin addictive?

Official regulatory documents classify the single-ingredient formulation of this medicine as not a controlled substance. The documents do not list addiction or abuse potential as a specific risk associated with its use.

Q: Can Alerfin be taken with other cold or flu medications?

According to official regulatory documents, caution is advised when combining Alerfin with cold or flu medications. This is because many over-the-counter remedies contain ingredients that can increase the risk of drowsiness, sedation, or other central nervous system (CNS) depressant effects. Patients are advised to review the labels of other medicines to help ensure they are not taking multiple products with similar active ingredients.

Q: Are there any common foods or drinks to avoid while using Alerfin?

Official warnings strongly advise against consuming alcoholic beverages while using this medicine. Alcohol can cause an additive central nervous system (CNS) depressant effect, which greatly increases drowsiness and sedation. General warnings do not typically list specific food restrictions.

Q: Why do some people say Alerfin is different from other similar drugs?

Alerfin is classified as a first-generation antihistamine. This means that unlike some newer medications, it has characteristics that allow it to cross into the central nervous system. This classification is associated with its potential to cause a moderate degree of sedation and antimuscarinic effects, such as dry mouth.

Q: Is Alerfin prescribed for nasal congestion?

Official regulatory indications list the use of this medicine for allergic symptoms like sneezing, runny nose, and itching of the nose or throat. The drug is generally not indicated for relieving nasal congestion. Nasal congestion is often addressed by a different category of medicine called a decongestant.

Q: What makes Alerfin different from a decongestant?

Alerfin is an antihistamine, which works by blocking the effects of histamine released during an allergic reaction. In contrast, a decongestant belongs to a different drug class called sympathomimetic agents. These agents work by constricting blood vessels, which helps reduce swelling and relieve the feeling of nasal stuffiness.

Q: Can Alerfin be used by people who have asthma?

Official warnings advise that individuals with pre-existing breathing difficulties, including asthma or a lung condition like chronic bronchitis, caution is noted regarding the use of this medicine. This caution is noted because of its documented anticholinergic properties.

Q: Why is Alerfin used for conditions that aren't allergies?

While primarily used for allergic reactions, some regulatory documents do include its use for symptomatic relief of the common cold or cough. This is because its action as an antihistamine can help manage some of the symptoms associated with those conditions, such as a runny nose.

Q: What happens if someone misses a dose of Alerfin?

Official patient information advises that if a dose is forgotten or missed, the regulatory advice is to skip that dose entirely. Users are advised to then continue with the next scheduled dose at the usual time and not take a double dose.

Q: Does Alerfin interact with any common herbal supplements?

Official warnings advise caution when combining this medicine with herbal remedies and dietary supplements. Patients are advised to be particularly careful with products that may cause drowsiness, sedation, or anticholinergic effects (like dry mouth), as these side effects may be increased.

Q: Is it necessary to finish the entire course of Alerfin if symptoms improve?

Official instructions state that this medicine is for short-term, symptomatic relief and is typically taken 'as needed'. Unlike antibiotics or some other medications, it is not generally prescribed as a defined 'course' that must be completed once symptoms have resolved.

Q: What should be done if someone accidentally takes too much Alerfin?

Official warnings stress that an accidental overdose is considered a medical emergency. In the event that too much is taken, immediate emergency medical attention or contact with a Poison Control Center is required right away.

Q: Does Alerfin contain lactose?

Yes, according to official documentation, the tablet formulation of the medicine lists lactose (either Monohydrate or Anhydrous Lactose) as an inactive ingredient. This ingredient is included in the excipient list.

Q: Can Alerfin be crushed or split?

Official dosing instructions confirm that the immediate-release tablet formulation can be broken in half (split). This is often done to achieve the appropriate pediatric dose when using the medicine for children.

Q: Does Alerfin have a black box warning in the U.S.?

No, the single-ingredient formulation of this medicine does not carry an FDA Black Box Warning (BBW). This warning is sometimes present on certain combination products that include the medicine alongside other controlled substances, such as opioids.

Q: Where can I find the official prescribing information for Alerfin?

The official prescribing information can be found in documents published by government regulatory bodies. These documents include the Summary of Product Characteristics (SmPC) from authorities like the EMA, and the FDA DailyMed label in the United States.

How should Alerfin be stored and disposed of?

How to Store and Dispose of Alerfin

Adherence to official regulatory requirements ensures the stability and safety of Alerfin (Chlorphenamine Maleate).

Storage Requirements

Alerfin oral solution must be stored at room temperature below 25 C and kept in its original packaging. The container should remain tightly closed. It is a mandatory requirement to keep the medicine out of the reach and sight of children to prevent accidental ingestion. The product must be protected from direct sunlight and should not be used past the printed expiry date.

Disposal Instructions

Expired or unused Alerfin must not be discarded in general household waste or flushed down the sink. Official instructions require that the product be delivered to a designated pharmaceutical waste collection system to ensure proper environmental handling in accordance with local and national regulations.

Alerfin